atenolol has been researched along with Arteriosclerosis in 21 studies
Atenolol: A cardioselective beta-1 adrenergic blocker possessing properties and potency similar to PROPRANOLOL, but without a negative inotropic effect.
atenolol : An ethanolamine compound having a (4-carbamoylmethylphenoxy)methyl group at the 1-position and an N-isopropyl substituent.
Arteriosclerosis: Thickening and loss of elasticity of the walls of ARTERIES of all sizes. There are many forms classified by the types of lesions and arteries involved, such as ATHEROSCLEROSIS with fatty lesions in the ARTERIAL INTIMA of medium and large muscular arteries.
| Excerpt | Relevance | Reference |
|---|---|---|
| "In the Losartan Intervention for Endpoint Reduction in Hypertension (LIFE) study, there was a 25% risk reduction for stroke with angiotensin receptor blocker-based therapy (losartan) as compared with beta-blocker-based therapy (atenolol) despite comparable blood pressure reductions." | 9.12 | Long-term effects of a losartan- compared with an atenolol-based treatment regimen on carotid artery plaque development in hypertensive patients with left ventricular hypertrophy: ICARUS, a LIFE substudy. ( Fossum, E; Høieggen, A; Ibsen, H; Julius, S; Kjeldsen, SE; Olsen, MH; Reims, HM; Wachtell, K; Wan, Y, 2006) |
| "The European Lacidipine Study on Atherosclerosis (ELSA) is a prospective, randomized, double-blind, multinational trial comparing effects of 4-year treatment based on the long-acting, highly lipophilic calcium antagonist lacidipine with those of treatment based on the beta-blocker atenolol on the development of carotid artery wall alterations in patients (aged 45-75 years) with mild-to-moderate hypertension (systolic blood pressure 150-210 mmHg and diastolic blood pressure 95-115 mmHg)." | 9.08 | Risk factors associated with alterations in carotid intima-media thickness in hypertension: baseline data from the European Lacidipine Study on Atherosclerosis. ( Bond, MG; Dal Palù, C; Eckes, L; Hansson, L; Hennig, M; Magnani, B; Mancia, G; Neiss, A; Rahn, KH; Ravinetto, R; Reid, J; Rodicio, J; Safar, M; Zanchetti, A, 1998) |
| "The effects of SQ29,852 (n = 24), a new angiotensin converting enzyme inhibitor, and atenolol (n = 22), monotherapies were compared in 46 patients with mild to moderate essential hypertension." | 9.07 | Hypotensive effects and influence on serum lipids of SQ29,852, a new angiotensin converting enzyme inhibitor, in patients with essential hypertension: a comparison with atenolol. ( Doi, Y; Kagimoto, M; Kato, K; Kawasaki, K; Koga, S; Sakai, K; Sakaue, A; Sasaki, J; Takada, K; Takii, M, 1993) |
| "In the Losartan Intervention for Endpoint Reduction in Hypertension (LIFE) study, there was a 25% risk reduction for stroke with angiotensin receptor blocker-based therapy (losartan) as compared with beta-blocker-based therapy (atenolol) despite comparable blood pressure reductions." | 5.12 | Long-term effects of a losartan- compared with an atenolol-based treatment regimen on carotid artery plaque development in hypertensive patients with left ventricular hypertrophy: ICARUS, a LIFE substudy. ( Fossum, E; Høieggen, A; Ibsen, H; Julius, S; Kjeldsen, SE; Olsen, MH; Reims, HM; Wachtell, K; Wan, Y, 2006) |
| "The European Lacidipine Study on Atherosclerosis (ELSA) is a prospective, randomized, double-blind, multinational trial comparing effects of 4-year treatment based on the long-acting, highly lipophilic calcium antagonist lacidipine with those of treatment based on the beta-blocker atenolol on the development of carotid artery wall alterations in patients (aged 45-75 years) with mild-to-moderate hypertension (systolic blood pressure 150-210 mmHg and diastolic blood pressure 95-115 mmHg)." | 5.08 | Risk factors associated with alterations in carotid intima-media thickness in hypertension: baseline data from the European Lacidipine Study on Atherosclerosis. ( Bond, MG; Dal Palù, C; Eckes, L; Hansson, L; Hennig, M; Magnani, B; Mancia, G; Neiss, A; Rahn, KH; Ravinetto, R; Reid, J; Rodicio, J; Safar, M; Zanchetti, A, 1998) |
| "The effects of SQ29,852 (n = 24), a new angiotensin converting enzyme inhibitor, and atenolol (n = 22), monotherapies were compared in 46 patients with mild to moderate essential hypertension." | 5.07 | Hypotensive effects and influence on serum lipids of SQ29,852, a new angiotensin converting enzyme inhibitor, in patients with essential hypertension: a comparison with atenolol. ( Doi, Y; Kagimoto, M; Kato, K; Kawasaki, K; Koga, S; Sakai, K; Sakaue, A; Sasaki, J; Takada, K; Takii, M, 1993) |
| "Aortic stiffness and left ventricular hypertrophy (LVH) are predictors of mortality in hemodialysis (HD) patients." | 2.71 | Inflammation, arteriosclerosis, and cardiovascular therapy in hemodialysis patients. ( Adda, H; Guerin, AP; London, GM; Marchais, SJ; Metivier, F; Pannier, B, 2003) |
| " Conclusively, nipradilol, beta-blocker with nitric oxide-releasing action, in contrast to the other beta-blockers and nitric oxide donors, showed a successful anti-atherosclerotic effect through the restoration of nitric oxide bioavailability and possible interaction with oxygen radicals." | 1.31 | Anti-atherosclerotic effect of beta-blocker with nitric oxide-releasing action on the severe atherosclerosis. ( Hayashi, T; Iguchi, A; Kano, H; Matsui-Hirai, H; Sumi, D; Thakur, NK; Tsunekawa, T, 2002) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 4 (19.05) | 18.7374 |
| 1990's | 6 (28.57) | 18.2507 |
| 2000's | 11 (52.38) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Ariff, B | 1 |
| Stanton, A | 1 |
| Barratt, D | 1 |
| Augst, A | 1 |
| Glor, F | 1 |
| Poulter, N | 1 |
| Sever, P | 1 |
| Xu, Y | 1 |
| Hughes, A | 1 |
| Thom, SA | 1 |
| Bossi, M | 1 |
| Tiberti, G | 1 |
| London, GM | 1 |
| Marchais, SJ | 1 |
| Guerin, AP | 1 |
| Metivier, F | 1 |
| Adda, H | 1 |
| Pannier, B | 1 |
| Torella, F | 1 |
| de Cossart, L | 1 |
| Dimitri, SK | 1 |
| Edwards, PR | 1 |
| Giannattasio, C | 1 |
| Failla, M | 1 |
| Hennig, M | 3 |
| Hollweck, R | 1 |
| Laurent, S | 1 |
| Mallion, JM | 1 |
| Reid, J | 2 |
| Safar, M | 3 |
| Bond, G | 2 |
| Zanchetti, A | 3 |
| Mancia, G | 3 |
| Fossum, E | 1 |
| Olsen, MH | 1 |
| Høieggen, A | 1 |
| Wachtell, K | 1 |
| Reims, HM | 1 |
| Kjeldsen, SE | 1 |
| Ibsen, H | 1 |
| Wan, Y | 1 |
| Julius, S | 1 |
| Vidt, DG | 1 |
| Dal Palú, C | 2 |
| Hansson, L | 2 |
| Magnani, B | 2 |
| Neiss, A | 2 |
| Rahn, KH | 2 |
| Reid, JL | 1 |
| Rodicio, JL | 1 |
| Sasaki, J | 1 |
| Koga, S | 1 |
| Kato, K | 1 |
| Takii, M | 1 |
| Sakai, K | 1 |
| Kawasaki, K | 1 |
| Kagimoto, M | 1 |
| Doi, Y | 1 |
| Takada, K | 1 |
| Sakaue, A | 1 |
| Leonetti, G | 1 |
| Bond, MG | 3 |
| Mercuri, M | 1 |
| Seifert, T | 1 |
| Zschörnig, O | 1 |
| Arnhold, J | 1 |
| Arnold, K | 1 |
| Rodicio, J | 1 |
| Eckes, L | 1 |
| Ravinetto, R | 2 |
| Tang, R | 1 |
| Thomasson, B | 1 |
| Scherz, R | 1 |
| Catalini, R | 1 |
| Rubba, P | 1 |
| Einecke, D | 1 |
| Thakur, NK | 1 |
| Hayashi, T | 1 |
| Sumi, D | 1 |
| Kano, H | 1 |
| Matsui-Hirai, H | 1 |
| Tsunekawa, T | 1 |
| Iguchi, A | 1 |
| Komai, N | 1 |
| Ohishi, M | 1 |
| Morishita, R | 1 |
| Moriguchi, A | 1 |
| Kaibe, M | 1 |
| Matsumoto, K | 1 |
| Rakugi, H | 1 |
| Higaki, J | 1 |
| Ogihara, T | 1 |
| Lee, RJ | 1 |
| Dickerson, DD | 1 |
| Fulmor, IE | 1 |
| Goldberg, ME | 1 |
| Nafstad, I | 1 |
| Tollersrud, S | 1 |
| Eriksen, K | 1 |
| Helgeland, A | 1 |
| Solberg, LA | 1 |
| Bredesen, J | 1 |
| Dale, O | 1 |
| Brook, JG | 1 |
| Marmur, A | 1 |
| Berkovitch, Y | 1 |
| Aviram, M | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Triple-Blind, Parallel Study to Investigate the Effect of Losartan Versus Atenolol on the Reduction of Morbidity and Mortality in Hypertensive Patients With Left Ventricular Hypertrophy[NCT00338260] | Phase 3 | 496 participants (Actual) | Interventional | 1995-06-30 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
1 review available for atenolol and Arteriosclerosis
| Article | Year |
|---|---|
Advances in the medical management of renovascular hypertension.
Topics: Adult; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Arteriosclerosis; Atenolol | 1984 |
10 trials available for atenolol and Arteriosclerosis
| Article | Year |
|---|---|
Comparison of the effects of antihypertensive treatment with angiotensin II blockade and beta-blockade on carotid wall structure and haemodynamics: protocol and baseline demographics.
Topics: Adrenergic beta-Antagonists; Adult; Aged; Aged, 80 and over; Angiotensin II; Antihypertensive Agents | 2002 |
Inflammation, arteriosclerosis, and cardiovascular therapy in hemodialysis patients.
Topics: Adult; Antihypertensive Agents; Aortic Diseases; Arteriosclerosis; Atenolol; Blood Pressure; C-React | 2003 |
Different relation between 24-h blood pressure and distensibility at different peripheral arteries. Data from the European Lacidipine Study on Atherosclerosis (ELSA).
Topics: Antihypertensive Agents; Arteriosclerosis; Atenolol; Blood Pressure; Blood Pressure Monitoring, Ambu | 2005 |
Long-term effects of a losartan- compared with an atenolol-based treatment regimen on carotid artery plaque development in hypertensive patients with left ventricular hypertrophy: ICARUS, a LIFE substudy.
Topics: Adrenergic beta-Antagonists; Aged; Angiotensin II Type 1 Receptor Blockers; Arteriosclerosis; Atenol | 2006 |
The E.L.S.A. trial: protocol of a randomized trial to explore the differential effect of antihypertensive drugs on atherosclerosis in hypertension.
Topics: Aged; Antihypertensive Agents; Arteriosclerosis; Atenolol; Dihydropyridines; Double-Blind Method; Hu | 1994 |
Hypotensive effects and influence on serum lipids of SQ29,852, a new angiotensin converting enzyme inhibitor, in patients with essential hypertension: a comparison with atenolol.
Topics: Adult; Aged; Analysis of Variance; Angiotensin-Converting Enzyme Inhibitors; Apolipoproteins; Arteri | 1993 |
[The preliminary clinical evidence from the ELSA study. The European Lacidipine Study on Atherosclerosis].
Topics: Aged; Antihypertensive Agents; Arteriosclerosis; Atenolol; Calcium Channel Blockers; Carotid Artery | 1995 |
Potential modification of plaque behavior through the European lacidipine study on atherosclerosis.
Topics: Adrenergic beta-Antagonists; Arteriosclerosis; Atenolol; Blood Pressure Monitoring, Ambulatory; Calc | 1995 |
Risk factors associated with alterations in carotid intima-media thickness in hypertension: baseline data from the European Lacidipine Study on Atherosclerosis.
Topics: Adrenergic beta-Antagonists; Aged; Arteriosclerosis; Atenolol; Blood Pressure; Calcium Channel Block | 1998 |
Baseline reproducibility of B-mode ultrasonic measurement of carotid artery intima-media thickness: the European Lacidipine Study on Atherosclerosis (ELSA).
Topics: Adrenergic beta-Antagonists; Arteriosclerosis; Atenolol; Calcium Channel Blockers; Carotid Arteries; | 2000 |
10 other studies available for atenolol and Arteriosclerosis
| Article | Year |
|---|---|
[Ischemic heart disease in patients with arteriopathies].
Topics: Adrenergic beta-Antagonists; Angina Pectoris; Angina, Unstable; Antihypertensive Agents; Arterioscle | 2002 |
Routine beta-blockade in vascular surgery.
Topics: Adrenergic beta-Antagonists; Aged; Amputation, Surgical; Analysis of Variance; Arteriosclerosis; Ate | 2003 |
Beta-blockers inhibit the modification of low-density lipoproteins by sodium hypochlorite in vitro.
Topics: Acebutolol; Adrenergic beta-Antagonists; Alprenolol; Anti-Inflammatory Agents, Non-Steroidal; Arteri | 1997 |
[ELSA Studies studies progression of atherosclerosis. Calcium antagonist arrests the process more than a beta-blocker].
Topics: Adrenergic beta-Antagonists; Arteriosclerosis; Atenolol; Calcium Channel Blockers; Dihydropyridines; | 2001 |
[Calcium antagonists lower not only blood pressure. Arteriosclerosis is braked too].
Topics: Aged; Antihypertensive Agents; Arteriosclerosis; Atenolol; Calcium Channel Blockers; Carotid Stenosi | 2001 |
Anti-atherosclerotic effect of beta-blocker with nitric oxide-releasing action on the severe atherosclerosis.
Topics: Adrenergic beta-Antagonists; Animals; Aorta, Thoracic; Arteriosclerosis; Atenolol; Blood Pressure; C | 2002 |
Serum hepatocyte growth factor concentration is correlated with the forearm vasodilator response in hypertensive patients.
Topics: Antihypertensive Agents; Arteriosclerosis; Atenolol; Blood Pressure; Cilazapril; Endothelium, Vascul | 2002 |
Direct myocardial depressant effects of several beta-adrenergic blocking agents in the unanesthetized atherosclerotic rabbit.
Topics: Adrenergic beta-Antagonists; Alprenolol; Animals; Arteriosclerosis; Atenolol; Blood Pressure; Depres | 1978 |
The influence of atenolol and prazosin on serum lipids and atherosclerosis in minipigs fed a hyperlipidemic diet.
Topics: Animals; Arteriosclerosis; Atenolol; Body Weight; Cholesterol, Dietary; Diet; Female; gamma-Glutamyl | 1988 |
Platelet adhesion in hyperlipidemic and hypertensive patients.
Topics: Adult; Arteriosclerosis; Atenolol; Humans; Hypercholesterolemia; Hyperlipidemias; Hyperlipoproteinem | 1985 |